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Abstract
Background: Colorectal cancer survivors are not only at risk for recurrent disease but also at increased risk of
comorbidities such as other cancers, cardiovascular disease, diabetes, hypertension and functional decline. In this
trial, we aim at investigating whether a diet in accordance with the Norwegian food-based dietary guidelines and
focusing at dampening inflammation and oxidative stress will improve long-term disease outcomes and survival in
colorectal cancer patients.
Methods/design: This paper presents the study protocol of the Norwegian Dietary Guidelines and Colorectal Cancer
Survival study. Men and women aged 50–80 years diagnosed with primary invasive colorectal cancer (Stage I-III) are
invited to this randomized controlled, parallel two-arm trial 2–9 months after curative surgery. The intervention group
(n = 250) receives an intensive dietary intervention lasting for 12 months and a subsequent maintenance intervention
for 14 years. The control group (n = 250) receives no dietary intervention other than standard clinical care. Both groups
are offered equal general advice of physical activity. Patients are followed-up at 6 months and 1, 3, 5, 7, 10 and 15 years
after baseline. The study center is located at the Department of Nutrition, University of Oslo, and patients are recruited
from two hospitals within the South-Eastern Norway Regional Health Authority. Primary outcomes are disease-free
survival and overall survival. Secondary outcomes are time to recurrence, cardiovascular disease-free survival,
compliance to the dietary recommendations and the effects of the intervention on new comorbidities, intermediate
biomarkers, nutrition status, physical activity, physical function and quality of life.
Discussion: The current study is designed to gain a better understanding of the role of a healthy diet aimed
at dampening inflammation and oxidative stress on long-term disease outcomes and survival in colorectal
cancer patients. Since previous research on the role of diet for colorectal cancer survivors is limited, the study
may be of great importance for this cancer population.
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Background
The incidences of colorectal cancer (CRC) are 5–10
times higher in Europe, North America and Oceania
than in countries in Africa, south Asia and Central
America [1], and the incidence in Norway is among the
highest in the world [2]. Established risk factors for CRC
are age, family history of CRC, inherited syndromes (Fa-
milial adenomatous polyposis, Lynch syndrome) and in-
flammatory bowel disease. In addition, several
modifiable lifestyle-related risk factors are associated
with CRC. Those include smoking, body fatness, abdom-
inal fatness, diabetes, physical inactivity and an un-
healthy diet (high consumption of alcohol, red and
processed meat, and low consumption of foods contain-
ing dietary fibre) [3, 4]. World Cancer Research Fund
(WCRF)/American Institute for Cancer Research (AICR)
estimates that about 45% of all CRC cases could be pre-
vented by improved lifestyle [3].
About 40% of CRC patients [5] have at least one con-
comitant disease (e.g. hypertension, cardiovascular dis-
ease (CVD), diabetes, chronic obstructive pulmonary
disease or other malignancies) at the time of diagnosis
and increased risk of developing additional comorbidi-
ties after CRC diagnosis [6–10]. These comorbid condi-
tions may preclude or reduce effect of treatment, and
consequently reduce disease-specific and total survival
[8, 11, 12].
While it is well established that an unhealthy diet in-
creases risk of CRC (e.g. see the latest update from
World Cancer Research Fund, 2011 [4]) there are few
studies that have focused on the effect of diet on disease
outcomes and survival [13–15]. In paucity of data, health
authorities in most countries recommend the same diet
to CRC survivors (i.e. patients living with a CRC diagno-
sis, including those who have recovered) as to people
without a cancer diagnosis [3].
Inflammation and oxidative stress are central under-
lying disease mechanisms in cancer and several other
chronic diseases. Recent research suggests that there are
two major molecular pathways leading to CRC, both of
which involve inflammation and oxidative stress as
major driving forces. The majority of CRC cases may be
due to molecular events that result in chromosomal in-
stability, while about 20-30% of CRCs are due to gene
hypermethylation (called CpG island methylator ph-
enotype (CIMP)) [16–18]. A large proportion of the
CRC cases due to CIMP display microsatellite instability
[18, 19]. In total, about 70 mutations in different genes
have been identified as relevant for these two pathways
to CRC, and it is assumed that each individual CRC
tumor accumulates an average of 9 CRC pathogenic mu-
tations out of this total pool of 70 mutations [16].
The heterogeneous pathogenesis of CRC comply with
the hallmarks of cancer defined by Hanahan and
Weinberg [20] and the cancer genome landscape as de-
fined by Vogelstein et al [21]. Underlying these hall-
marks of cancer, Hanahan and Weinberg proposed that
genome instability and inflammation are two underlying
driving forces [20]. These two processes or mechanisms
are closely intertwined, since inflammation is a major
cause of oxidative stress, and oxidative stress is a major
cause of genome instability. Although inflammation and
oxidative stress ultimately may be related to all CRC
cases, the degree of inflammation and oxidative stress
may vary significantly with the molecular signature
present in the individual CRC patient [22].
In clinical trials and various models systems, we have
identified a number of plant foods (e.g. berries, nuts,
spices, coffee and specific fruits and vegetables) with the
potential of dampening inflammation and oxidative
stress [23–29]. Furthermore, a number of studies have
also suggested that adherence to a prudent diet (e.g.
Mediterranean diet) reduce inflammation and oxidative
stress [30, 31]. We suggest that a prudent diet rich in
specific plant-foods may be beneficial for CRC patients,
especially those CRC cases with molecular signatures
creating major inflammation and oxidative stress.
No intervention studies have investigated the role of
diet in disease outcomes and survival in CRC-patients
after diagnosis. Furthermore, no previous diet interven-
tion study has focused on dampening inflammation and
oxidative stress in this cancer population. This paper
presents the background and design of a randomized
controlled food-based diet intervention that examines
the effects on disease outcomes and survival in CRC sur-
vivors. The diet intervention includes foods and drinks
that have been suggested to dampen inflammation and
oxidative stress. While specific anti-inflammatory and
antioxidant-rich foods are emphasized in each food cat-
egory, the complete intervention is fully in accordance
with the prudent diet recommended by the Norwegian
food-based dietary guidelines (NFBDG) [32] (i.e. a diet
similar to the Mediterranean diet).
Objectives
Outcomes are inconsistently defined in many clinical
cancer trials [33, 34]. For the primary outcomes, we
have used the proposed guidelines for outcomes as
described by Punt et al [34]. The two primary out-
comes are (to be assessed when all patients have
completed 5, 10, and 15 years, respectively, of follow-
up after baseline):
1. Disease-free survival (DFS) (events are defined as
detection of local recurrence or metastasis or any
second cancer or death from any cause)
2. Overall survival (OS) (event is defined as death
from any cause)
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Secondary outcomes are:
I. Time to recurrence (events are defined as detection
of local recurrence or metastasis)
II. CVD -free survival (events of CVD (ICD-10;
chapter I) or death from any cause)
III. CRC-specific survival (death due to CRC)
IV. Total cancer-specific survival (death due to CRC or
any other cancer)
V. Inflammatory disease-specific survival (death due
to inflammatory disease)
VI. Cardiovascular (CVD)-specific survival (death due
to CVD)
VII.New morbidity of other diet-related chronic
diseases (e.g. ischemic coronary heart disease,
cerebrovascular disease, thromboembolic disease,
type 2 diabetes, obesity, hypertension and chronic
obstructive pulmonary disease)
VIII.Dietary intake and nutritional status
IX. Physical activity and function
X. Nutrition biomarkers (e.g., carotenoids, fatty acids,
25-hydroxy vitamin D)
XI. Body composition
XII. Anthropometric measures (e.g. weight, waist and
hip circumference)
XIII.Biomarkers for inflammation and oxidative stress
(e.g. isoprostanes, cytokines)
XIV.Transcription- and epigenetic profiles
XV. Biomarkers for cardiovascular disease, metabolic
syndrome, type 2-diabetes, thromboembolic
disease and cancer (e.g. blood pressure, total/LDL-
cholesterol, HbA1c, CRP, IL-6, IL-10, TNFα)
XVI.Health related quality of life and fatigue
The secondary outcomes will be assessed after 5, 10,
and 15 years and described in detail in subsequent re-
ports. In addition, intervention effects on secondary out-
comes VII-XVI will also be assessed at 6 months, 1 year
and 3 years follow-up.
Methods and Design
Study design
The CRC-NORDIET study is a multicentre, randomized
controlled trial (RCT), with two parallel study arms. The
intervention group receives an intensive dietary inter-
vention and general advice on physical activity (see
below), whereas the control group only receives standard
general dietary advice and general advice on physical
activity. Newly diagnosed CRC patients undergoing sur-
gery are recruited to the study. In addition, an age-
matched CRC-free reference group (will be published
elsewhere) will also be included. The intervention starts
2–9 months after surgery (i.e. baseline), and consists of
two periods: an intensive period that lasts 12 months,
and a subsequent maintenance period which lasts an
additional 14 years. Patients are invited to the study
centre, situated at the Department of Nutrition, Univer-
sity of Oslo, at baseline, 6 and 12 months after baseline,
and 3, 5, 7, 10 and 15 years after baseline. Additional
follow-ups by regular mail, phone and e-mail, occur
throughout the study. The study flow diagram is pre-
sented in Fig. 1. The design and handling of data of the
CRC-NORDIET study is in fully agreement with the
CONSORT statement [35].
Patients and eligibility
Men and women 50 to 80 years of age with newly diag-
nosed primary invasive colorectal cancer (ICD-10 18-
20), staged I-III (TNM-staging system [36]) are eligible
for the study. The patients must be able to read and
understand Norwegian and to provide a signed informed
written consent. Patients unable to perceive information
and understand the intervention due to diagnosed de-
mentia, or altered mental status as well as patients par-
ticipating in other RCTs in conflict with our trial are
excluded from the study. Precise inclusion and exclusion
criteria are presented in Table 1.
Recruitment and randomization
Patients are recruited from Oslo University Hospital and
Akershus University Hospital within the South-Eastern
Norway Regional Health Authority. Screening for eli-
gible patients is performed by research investigators in
cooperation with hospital personnel by monthly reviews
of surgery lists and medical records. Eligible patients are
invited within 9 months from surgery.
Patients accepting the invitation sign an informed con-
sent. Signed informed consent gives permission to the
study personnel to take biological samples, perform
physical measurements, and retrieve information from
medical records, health registries and questionnaires. In-
formation about storage of biological materials and use
of individual data retrieved during the whole study for
analysis and publishing purposes is also included in the
informed consent letter.
Prior to baseline of the intervention, patients are ran-
domized to either intervention group A or control group
B in blocks of four. The random number sequence is
computer-generated for each hospital. The person
who generates the allocation sequence is neither the
same person who determines eligibility nor the person
that informs patients about their allocated study
group. The patients are informed about the study
group assignment at the baseline visit. Due to the na-
ture of the intervention, neither the registered dieti-
tians, nor the other research coworkers who meet the
patients at the study centre, nor the patients them-
selves are blinded to group allocation.
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Intensive period of intervention
The CRC-NORDIET study offers an extensive interven-
tion program for patients in group A, consisting of indi-
vidual counselling on nutrition and physical activity,
grocery discount cards, delivery of free food items, group
meetings, printed materials, access to a CRC-NORDIET
webpage and contact by telephone and e-mail. The pa-
tients in group B are offered the same individual coun-
selling on physical activity as group A, as well as general
group meetings. An overview of the intervention pro-
gram and the instruments used are presented in Table 2
and Table 3, and in Additional file 1.
Group A: diet intervention
Colorectal cancer patients experience different disease
courses due to different stages at diagnosis, location of
tumor, surgical procedure and adjuvant treatment. The diet
intervention is therefore designed to meet the patients’ in-
dividual needs after surgery. In the initial phase, when
symptoms related to cancer and cancer treatment are most
common, the dietary focus is mainly on recovery and treat-
ment of symptoms and progressive weight loss. Later,
when symptoms and weight loss are treated and under
control, and the disease conditions are more stable, the
major focus is long-term disease-free living and secondary
preventions. In this phase, we emphasize a diet which may
dampen chronic inflammation and oxidative stress, fully in
accordance with the NFBDG. A number of strategies are
implemented to improve compliance to the recommended
diet of the CRC patients in group A (see below).
The dietary recommendations in the CRC-NORDIET
intervention The NFBDG, published in 2011, was de-
veloped to prevent chronic diseases in the general popula-
tion [32]. These guidelines are based on a comprehensive,
systematic review of the evidence linking diet to risk of
chronic diseases, including cancer. The guidelines do not
provide a detailed diet plan, but define major aspects of
the diet (Additional file 2). In the current study, the
particular focus will be on the following NFBDG
recommendations
1) daily intake of fruits, berries and vegetables
(≥500 g/day)
2) weekly intake of 300-450 g fish
3) daily intake of 70-90 g wholegrains
4) limiting red and processed meat to maximum
500 g/week
5) keeping body weight within normal range of body
mass index (BMI)
6) reduce intake of added sugar to < 10 E%
7) reduce salt intake to less than 6 g/day
8) achieving an average of at least 30 min of
moderate (3–6 metabolic equivalents (METs))
physical activity per day or 150 min of moderate
physical activity per week
The NFBDG can be implemented in different ways.
For example, the recommendations of eating 500 g
fruits, berries and vegetables every day may include
different selections of individual foods, all compliant
Fig. 1 Study flow diagram
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to the quantitative advice. However, not all of these
foods may dampen inflammation and oxidative
stress. Since inflammation and oxidative stress are
ubiquitous as common basic pathogenic mechanism,
we have selected to compose the intervention not
only according to the NFBDG, but also by emphasiz-
ing those foods with strongest evidence for dampen-
ing low grade chronic inflammation and oxidative
stress: We have identified foods and drinks that have
high contents of redox-active compounds and/or
have antioxidative effects individually or in combin-
ation in in vitro models, animal models, clinical tri-
als and/or epidemiological studies [23–26, 28, 29,
37–56] (detailed list with references in Additional
file 3):
 Drinks (e.g. coffee, black tea)
 Fruits and vegetables (e.g. onions, broccoli,
tomatoes, carrots, pomegranates, garlic,
oranges, olives)
 Berries (e.g. blueberries/bilberries, blackberries,
and raspberries)
 Nuts (e.g. walnuts, almonds, and hazel nuts)
 Herbs and spices (e.g. thyme, oregano, clove,
cinnamon, and rosemary)
 Whole grain (e.g. barley)
 Miscellaneous (dark chocolate)
Furthermore, we have also identified that the fol-
lowing foods and drinks may have anti-inflammatory
effects individually or in combination in cell cul-
tures, animal models, clinical trials and/or epidemio-
logical studies (detailed list with references in
Additional file 3):
Table 2 Instruments used to facilitate compliance in intervention group A during the first 12 months
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Table 1 Inclusion and exclusion criteria
Inclusion
criteria
Primary adenocarsinoma colorectal cancer
(ICD-10 C18-C20):








C18.7 Sigmoid colon (sigmoid (flexure)
C18.8 Overlapping lesion of colon
C18.9 Colon, unspecified
C19 Malignant neoplasm of rectosigmoid
junction
C20 Malignant neoplasm of rectum
TNM stage I-III
Age 50–80 years old
Exclusion
criteria
Colorectal adenoma, carcinoid, abdominal
carcinomatosis or sarcoma
Unable to read and understand Norwegian
Unable to perceive information and understand
the intervention as such due to dementia or
altered mental status
Unable to follow the dietary intervention due to
medical/clinical conditions e.g. total parental
nutrition, permanently institutionalized
Participation in another study in conflict with the
intention of the CRC-NORDIET study
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 Coffee
 Fruits and vegetables (e.g. tomatoes, carrots, dog
rose)
 Nuts (e.g. walnuts)
 Berries (e.g. strawberries, blueberries/bilberries, and
blackberries)
 Whole grains
 Herbs and spices (e.g. thyme, oregano, and
rosemary)
During the 15 year intervention period, these foods
and drinks are gradually implemented in the advice to
group A.
While these antioxidant- and phytochemical rich foods
are advised as part of a balanced diet according to the
NFBDG, patients were advised not to take any antioxi-
dant supplements [55, 57].
Intervention strategies
The following instruments are used to facilitate compli-
ance to the intervention in group A.
1. Individualized nutrition counselling by a registered
clinical dietitian.
The nutritional counselling aims to meet the individ-
ual nutritional needs as well as educate the patients on
how to change dietary habits in accordance with the
NGBDG. In order to individualize the dietary advice, the
registered clinical dietitian performs a comprehensive
evaluation in each of the meetings (Fig. 1). The Patient-
Generated Subjective Global Assessment (PG-SGA) tool
[58] is used to assess nutritional status and nutritional
impact symptoms. Weight and height measured the
same day is used to calculate BMI, and current weight is
compared with previous weight measurements to calcu-
late weight changes. The presence of stoma is recorded
as well as treatment status (i.e. whether or not the pa-
tient receives adjuvant treatment). Dietary intake is
assessed by 24-h recall (at baseline). In addition, the reg-
istered clinical dietitian characterizes the patient’s
current diet in relation to the NFBDG, and record use of
supplements.
When the nutritional evaluation is completed, the pa-
tient receives dietary advice based on nutritional status
and weight history. If the patient is malnourished or at
risk of malnutrition (i.e. PG-SGA category B or C), diet-
ary counselling primarily focuses on improving nutri-
tional status by treating symptoms, ensuring an
adequate energy and protein intake, and to prevent fur-
ther nutritional deterioration. In terms of progressive
weight loss, patients with PG-SGA B or C with BMI >20
are recommended to stabilize their body weight. Patients
with BMI < 20 are recommended to increase their body
weight within the range of a normal BMI, determined in
the current study as BMI 20–27 for patients aged 50–80
years [59, 60]. Well-nourished patients (i.e. PG-SGA cat-
egory A) with BMI >27 are recommended to decrease
their weight within normal BMI range. The recom-
mended change (weight gain or weight reduction) is set
to maximum 3 kg in 6 months to ensure an optimal
change in body composition.
If the patient is evaluated as well-nourished (PG-SGA
A), the dietary counselling primarily focuses on the
NFBDG. Examples of week menus are used to illustrate
examples of foods and amounts to be eaten in adherence
with the NFBDG. Food alternatives are given to adjust
the week menu to the patient’s personal eating habits
and preferences.
Motivation to change dietary habits in according to
the NFBDG is recorded by asking whether the patient
considers herself/himself to be either “very motivated”,
“motivated”, “less motivated” or “not motivated”. When
one of the last two categories is present, the registered
clinical dietitian explores the potential to increase motiv-
ation by using techniques from Motivational Interviewing
(MI) [61]. The degree of motivation (“very motivated”,
“motivated”, “less motivated” or “not motivated”) is taken
into account in each of the counselling sessions.
Each of the nutritional consultations is intended to re-
sult in a few dietary goals in agreement with the patient.
It is emphasized that the patient defines her/his personal
goals to increase the chances that he or she will succeed
in changing dietary habits. The registered clinical
dietitian aims at encouraging the patient to achieve these
goals and the goals will be revised at next session. The
telephone-based counselling in between the meetings at
the study centre focus at monitoring the patient’s body
weight status, dietary pattern according to the prede-
fined goals and motivational status. In addition to the
scheduled consultations at the study centre and by tele-
phone, the patients have the opportunity to contact the
registered clinical dietitian by e-mail during the entire
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intervention period. The same registered clinical
dietitian follows the patient during the entire interven-
tion period, when possible.
2. Discount card (25% discount on healthy foods)
The patients in the intervention group are offered a dis-
count card from the retailer company, “Norgesgruppen”,
which is Norway’s largest enterprise within the grocery
market, with a market share of 40%. The discount card
can be used within the first year of the intervention and
gives a 25% discount on all fresh vegetables, fruit, berries
and fish and on all food items marked with the keyhole
symbol, which is used by the health authorities to label
food that is considered the most healthy within its food
category [62]. The discount card can be used in all food
stores and supermarkets within “Norgesgruppen”.
3. Delivery of specific foods
The CRC-NORDIET is sponsored by several food pro-
ducing companies with free food items, specifically se-
lected in accordance with the anti-inflammatory and
antioxidant-rich foods emphasized in this study, such as
juice, garlic, tomato juice, fish, coffee, tea, cereals, whole
grain bread, oils etc. At all visits to the study centre, the
patients in group A receive a bag containing a mixture
of these food items. In addition, they receive a box with
free food items delivered to their homes two times dur-
ing the intensive period of the intervention.
4. CRC-NORDIET website
The patients in the intervention group get access to a
login-restricted, dynamic website with detailed informa-
tion about the NFBDG, portion sizes of recommended in-
take of fruits and vegetables and whole grain, food recipes,
examples of week menus, dietary advice for treatment-
related symptoms and advice on physical activity. In
addition, information about the CRC-NORDIET study
and contact information for the study organizers are
given. The website is continuously updated.
5. Printed materials
The patients in the intervention group receive printed
materials at the first visit to the study centre and at all
follow-ups to ensure that also patients who do not use
the internet get all relevant information.
6. Cooking course
During the first 6 months of the intervention, each pa-
tient in group A is offered a one-day cooking course.
This course is led by a registered clinical dietitian who
follows a protocol developed for the CRC-NORDIET
intervention. The aim of the cooking course is to give
the patients practical experience in making healthy
dishes and to introduce healthy choices when shopping
for food. The course consists of a one hour lecture on
the NFBDG and how to implement these guidelines in
daily cooking. All recipes can also be found on the CRC-
NORDIET web site.
7. Physical activity
The CRC-NORDIET study has an agreement with
“Active against cancer” [63], a non-governmental non-
profit organization founded in 2007. The organization
operates a free training studio (“Pusterommet”) for can-
cer patients at several hospitals in Norway. The physical
therapists working at these studios are instructed to give
individualized advice for exercises during and after can-
cer treatment. The CRC-NORDIET patients are encour-
aged to utilize this offer.
Moreover, the CRC-NORDIET patients are advised to
practice moderate physical activity for at least 30 min
per day, or 150 min per week, and they receive a booklet
on how to be physically active in daily life. In addition,
they are recommended to use local facilities, including
swimming pool, health training centres and walks in
their neighbourhoods.
8. Inspiration day
The patients in Group A are invited to an inspiration
day within the first 6 months of the intervention. The
day opens with a 45 min lecture about the aim and back-
ground of the CRC-NORDIET study by the project
leader, with special focus on the NFBDG. The patients
are shown examples of different portion sizes of fruits
and vegetables, nuts, whole grain products, the food-
dish-model, and have the opportunity to talk to regis-
tered clinical dieticians. The last part of the inspiration
day focuses on physical activity, and starts with a lecture
about physical activity incorporated in daily life. The pa-
tients also meet the physical therapists from “Pusterom-
met”. The meeting ends with a lunch and a quiz about
physical activity, and each patient receives a pedometer
as an incentive to be physically active.
9. Written reports
The patients receive reports from the non-biological
samplings (e.g. anthropometric measurements and blood
pressure, described in detail in the following section)
performed at the three time points during the intensive
intervention period (baseline, 6 and 12 months after
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baseline), as well as a one-year report showing the devel-
opment during the last year. Reports from the physical
activity monitors are given to the patients after the first
intensive year of intervention.
Group B: control group
1. Physical activity
Patients in the control group receive the same basic
advice on physical activity as well as free access to the
training studio as patients in the intervention group (see
above).
2. Inspiration day
The inspiration day is structured identically as for group
A, except for the session focusing particularly on diet,
which is excluded in the inspiration day for group B.
3. Dietary information
The patients in group B receive a booklet with basic
dietary advice at baseline. In contrast to the intervention
group, the control group receives no individualized diet-
ary advice adapted to their eating habits and preferences.
If they seek counselling concerning symptoms related to
cancer or cancer treatment, the registered clinical dieti-
tians provide dietary advice based on information from
booklets and other printed materials already available in
the hospitals. This information and dietary advice is con-
sidered as part of the standard care.
4. Written reports
The patients in group B receive written reports simi-
larly as group A after all visits during the intensive inter-
vention period.
Moderate intervention during maintenance
period (year 2–15)
During the maintenance period, which starts after the
first intensive year and lasts for 14 years, both groups re-
ceive reports (e.g. anthropometric measurements and
blood pressure) following every visit at study centre
(year 3, 5, 7, 10 and 15).
The patients in group A are invited to an inspiration
day every year during moderate period of intervention.
The aim of these meetings is to maintain the focus on
foods dampening inflammation and oxidative stress and
the NFBDG, and to encourage the patients to continue
following the guidelines in a long-term perspective. In
addition, group A are offered dietary counselling at each
visit at the study centre, as well as a telephone
counselling by the registered clinical dietitians once a
year. They also have access to the CRC-NORDIET web-
page which is continuously updated with information
and encouragements (e.g. recipes, nutrition information,
motivational tips and relevant popular reports from nu-
tritional sciences) until the end of study participation.
An overview of the instruments used during the main-
tenance period is presented in Table 4.
Assessment of primary outcomes
Several registries and medical records will be used for
assessment of primary outcomes. The registries and time
points for primary outcome assessment are summarized
in Table 5.
Questionnaires, biological samplings and measurements
Group A and Group B are undergoing equal regimes of
measurements and biological samplings at all visits
(Additional file 4). All patients are also asked to
complete several questionnaires regarding demographic
information, dietary intake, health status and physical
activity (described below) (Additional file 4). The ques-
tionnaires administered at baseline of intervention are
also completed at 6 months and 12 months follow-up.
After the first year, the patients are invited to the study
centre for questionnaires, biological samplings and mea-
surements 3, 5, 7, 10 and 15 years after baseline. In
addition to the visits to the study centre during the
maintenance period, finger prick blood sample equip-
ment (dried blood-spot cards) and questionnaires are
sent to the patients’ home at certain time points and
subsequently returned to the study centre.
Demographic information
A short questionnaire is used to assess demographic
characteristics including age, gender, marital status, eth-
nicity, level of education, working status, family history
of CRC or other type of cancer.
Table 4 Instruments offered to the respective groups during
maintenance period of intervention
Instruments Time points
2, 4, 6, 8, 9, 11,
12, 13, 14 years
3, 5, 7, 10,
15 years
Dietary counselling at study centre
(Group A)
X
Dietary counselling by telephone
(Group A)
X X







measurements (Group A and B)
X
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Assessment of dietary intake
Semi-quantitative food frequency questionnaire (FFQ)
The semi-quantitative 282-item FFQ used in CRC-
NORDIET is designed to assess habitual diet over the
preceding year, including both frequency of intake and
portion sizes. The FFQ is described and validated else-
where [64, 65].
Compliance questionnaire The compliance question-
naire is a semi-quantitative short 63-item FFQ, devel-
oped within this study and designed to assess the dietary
intake (grams per day) and physical activity (minutes per
day) for the last 1–2 months. The questions correspond
to the food groups and the recommendations regarding
physical activity of the NFBDG. The questionnaire will
be validated within the first period of study.
Food records Food intake is recorded by using a 7-days
weighed food record. The patients are provided with a
food diary and a digital scale, and are instructed on how
to weigh and record all foods and beverages consumed
during a period of seven days. The food diary include all
days of a week, and can either record seven consecutive
days or be divided into two periods of three and four
days within two weeks. The food records are performed
in a subgroup of patients (will be published elsewhere).
24-h recall A registered clinical dietitian performs a 24-
h recall at baseline by asking the patients in the inter-
vention group in details about the intake of foods and
drink during the past 24-h period. The 24-h recall is per-
formed only in intervention patients since it is an inte-
grated part of the nutritional counselling.
Assessment of physical activity and function
Recording of daily physical activity The physical activ-
ity monitor SenseWear Mini Armband (BodyMedia,
Pittsburgh, Pennsylvania, USA) [66] is used to record
daily physical activity, inactivity and energy expenditure
during seven consecutive days among all patients in both
study arms at all visits. The armband monitors
physiological data such as heat flux, galvanic skin re-
sponse, 3-axis accelerometer and skin temperature. All
data are retrieved from the armband to the computer
with the SenseWear Professional Software [66]. The par-
ticipant are instructed how to use the armband, and re-
turn it in a stamped envelope to the CRC-NORDIET
study at the end of the test period. The armband is pre-
programmed with the co-predictors such as weight,
height, age, gender, smoking status (smoker/non-
smoker) and placed around the non-dominant arm.
Self-reported physical activity The patients are asked
to complete a questionnaire regarding frequency, intensity
and duration of their daily physical activity, as well as dur-
ation of sedentary time. These questions are based on the
questionnaire from the HUNT 3 study in Norway [67].
6-min walking test Patients are invited to a 6-min walk
test (6MWT) at several time points. The test is per-
formed indoors, along a long, flat, straight, enclosed cor-
ridor with a hard surface. The walking course is 30 m in
length, and cones mark the turnaround points. A count-
down timer (or stopwatch) is used to record the time of
the test. Prior to the test, the researcher measures the
blood pressure of the patient. In addition, the pulse is
monitored before, during and after the test. The patients
are asked to grade its level of shortness of breath and
the level of fatigue by using the Borg scale 6-20 before
and after the test. Total length of walking (in meters) is
recorded during 6 min of time.
Sit-to-stand test The test is performed by the use of a
straight back chair with a solid seat at the height of
44 cm. The patients are instructed to sit on the chair
with arms folded across their chest, and then to stand
up and sit down as quickly and frequently as possible
within 30 s, keeping both arms folded across the chest.
The number of stands during this period is counted.
Handgrip strength Hand-grip strength is measured by
the MAP 80 K1 Hand grip dynamometer (KERN &
SOHN GmbH, Balingen, Germany) and measured as de-
scribed in the manufacturer’s protocol [68]. The max-
imal strength of hand grip (kg) is recorded. For women
and men, a 40 kg- and 80 kg-spring is used, respectively.
The grip strength is measured with one punch and re-
peated three times on both hands. The maximum hand-
grip strength on both left and right hands are recorded.
Assessment of nutritional status
Patient-Generated Subjective Global Assessment
(PG-SGA) Nutritional status is measured by using the
scored PG-SGA [58], a nutritional assessment tool spe-
cifically developed and validated for cancer patients. A
Table 5 Data source used to assess primary outcomes









DFS Colorectal Cancer Registry of
Norway, Cancer Registry of






OS Cause of Death Registry in
Norway
X X X
DFS disease-free survival, OS overall survival
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translated (Norwegian) version is used. Both the global
categories well-nourished (A), moderate malnourished
(B) and severe malnourished (C), as well as the numer-
ical scoring system are used to characterize the nutri-
tional status.
Anthropometric measurements
Body weight Body weight (kg) is measured by using a
non-slip Marsden M-420 Digital Portable Floor Scale
(Marshden, Rotherham, South Yorkshire, United Kingdom)
or a digital wireless measuring station for height and
weight, Seca 285 (Seca, Birmingham, United Kingdom)
[69]. Measurements are performed with light clothes and
without shoes. Body weight is recorded with 2 decimals
and the kind of clothing is recorded.
Height Height (cm) is measured using either a mechan-
ical height rod (Kern MSF- 200, [68]) or a digital wire-
less stadiometer (Seca 285 [69]). The height is recorded
with one decimal precision.
Waist and hip circumference Waist circumference is
measured at the midpoint between the lower margin of
the last palpable rib and the top of the iliac crest,
whereas the hip circumference is measured around the
widest portion of the hips. Waist and hip circumference
are used to calculate the waist hip-ratio (WHR) which is
a well-established indicator of abdominal fatness [70].
Body composition analysis
Bioelectrical impedance analysis (BIA) BIA is per-
formed under standardized conditions by the use of BIA
101 (SMT Medical, Würzburg, Germany) that applies a
current of 0,8 μA at a frequency of 50 kHz. Four skin
electrodes are placed on hand and foot of the patients
when lying in supine position. All measurements are
conducted on the patients’ right side as instructed by
the manual. Resistance (Rz) and reactance (Xc) are used
in appropriate and validated equations to calculate body
composition compartments such as fat mass, fat free
mass and muscle mass. In addition, BIA is also per-
formed with Seca mBCA515 (Seca, Birmingham, United
Kingdom) [71]. Patients carrying a pacemaker are ex-
cluded from the BIA measurements.
Dual-energy x-ray absorptiometry (DXA) The Lunar
iDXA (GE Healthcare Lunar, Buckinghamshire, United
Kingdom) is used to measure bone mineral density and
body composition, including quantification of visceral fat.
Computed tomography (CT) CT images taken rou-
tinely for clinical purposes are used for body compos-
ition analysis, i.e. quantification of fat (visceral,
subcutaneous and intermuscular adipose tissue) and
skeletal muscle. The images are analysed using the Slice-
o-matic software, version 4.3 (Tomovision, Montreal,
Canada). The third lumbar vertebra (L3) is chosen as
standard landmark since skeletal muscle, lean tissue
mass and adipose tissue at this level are significantly cor-
related to whole-body tissue in healthy adults [72].
Blood pressure
Blood pressure (BP) is measured with the digital blood
pressure patient monitor Carescape V100 (GE Health-
care, Fairfield, USA) and performed by trained staff fol-
lowing the clinical procedure as described by the
manufacturer [73]. After a 5 min resting period in a si-
lent room, BP is measured four times on the non-
dominant arm with intervals of one minute.
Biobank
A variety of biological samples will be collected at differ-
ent time points during the study and will be used for the
purposes of measuring surrogate outcomes, biomarkers
of food intake and for identification of phenotypes asso-
ciated with different responses to the intervention.
Venous blood samples Overnight fasting blood samples
are taken between 07.30 and 10.30 at the study centre by
a trained technician. BD Vacutainer® (Becton, Dickinson
and Co, Franklin Lakes, NJ, USA) tubes are used to col-
lect ethylene diamine tetraacetic acid (EDTA) samples
(no. 367861 and 366643), serum samples (no 368774),
lithium heparin samples (no 367526), and citrate sam-
ples (no 369714).
Serum tubes are placed in room temperature for
30 min. Serum, EDTA and heparin samples are centri-
fuged at1500 g, 10 min, 15 °C. Serum, plasma and red
blood cells are aliquoted, and immediately stored in at
−80 °C until further analysis. Whole blood from EDTA
samples are also aliquoted for e.g. DNA extraction and
DNA damage/repair analysis The buffy coat from the
heparin samples are either frozen at −80 °C for later ana-
lysis or used to obtain isolated peripheral blood mono-
nuclear cells (PBMC) through Percoll centrifugation.
The isolated PBMCs from heparin samples are used for
ex vivo experiments. Two citrate tubes are kept 1 h re-
spectively at 4 °C and room temperature before centrifu-
gation (2500 g, 15 min, 4 °C) to obtain core plasma,
plasma and red blood cell aliquots that are stored at
-70 °C. One citrate tube is centrifuged (2500 g, 15 min,
4 °C) within 30 min of sampling, and core plasma is
stored at - 80 °C for further analysis of thromboembolic
factors. The citrate buffy coats are used to obtain iso-
lated PBMCs for the study of DNA repair and DNA
damage. PAXgene Blood RNA Tubes (cat.no 762115,
PreAnalytiX, Hombrechtikon, Switzerland) are used as
source for total blood RNA. The tubes are kept 2 h at
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room temperature before they are frozen at -20 °C for
24 h and subsequently transferred to −80 °C until time
for RNA isolation.
Isolation of buffy coats from EDTA samples The EDTA
buffy coats are re-solved in 9% NaCl (cat.no 586564,
B.Braun Melsungen AB, Melsungen, Germany) solution
before added on top of 4 ml Lymphoprep (cat.no
1114545, Axis-Shield, Oslo, Norway) in a 15 ml tube for
centrifugation (20 min RT 400 g) to isolate PBMCs
which are further used for a chromatin crosslinking pro-
cedure. The crosslink procedure for preparing the cell
pellets for ChIP-chip analysis are performed as follows:
Firstly, PBMCs are allowed to crosslink with 1% formal-
dehyde (final concentration) for 10 min at room
temperature, adding glycine (0.125 M) for 10 min at
room temperature to stop the crosslinking process. After
washing the cell pellets twice with 10 mL of ice-cold 1 ×
PBS the pellets are immediately stored in 2 ml plastic
tubes at −80 °C until proceeding further with protocols
for Chip-on-Chip analysis at a later time point.
Finger prick blood samples Finger prick blood samples
for analysis of e.g. biomarkers of dietary intake, oxidative
stress and oxidative damage are collected by the dried
blood spots (DBS) method as previously described [74].
DBS cards (2 cards per patient) are allowed to dry in
room temperature for 2 h and are frozen at −80 °C in
airtight aluminium bag with a desiccant until further
analysis.
Urine samples Biomarkers of food intake, oxidative
stress and other risk factors related to the progression of
CRC will be measured in urine. Urine samples are col-
lected from a subpopulation several times during the inter-
vention by the methods as previously described [75–77].
Faeces samples Microbiotica and biomarkers related to
CRC will be measured in faeces samples which are col-
lected from a subpopulation several times during the
intervention. The patients will receive a specific faeces
sample tool kit and are asked to collect the sample at
home and mail it to the study centre. Sampling and ana-
lysing of the faeces samples will be performed by follow-
ing the procedure as described by Naseribafrouei [78].
Tumour tissue Molecular signatures in CRC tumours
that are linked to inflammation, oxidative stress and en-
ergy balance have been shown to predict response to
lifestyle intervention. Characterization of tumor markers
will be performed by immunohistochemistry, PCR, se-
quencing and q‐PCR (to be published elsewhere). Fur-
thermore, we will study whether tumor markers predict
response to the dietary intervention. Samples of tumor
tissue are collected at surgery in collaboration with the
hospitals. Molecular signature data are also obtained
from the CRC biobank project at the Oslo University
Hospital.
Oral glucose tolerance test
Prior to the oral glucose tolerance test, the patient is
fasting for at least 8 h. Blood samples (serum and PAX
tubes) are taken, and blood glucose is measured with a
blood glucose meter [79]. The patients are asked to
drink 75 g of glucose (D (+)-Glucose (product number:
1370485000, Merck-Millipore Corp, Darmstadt,
Germany) in 4 dl of boiled water. The glucose liquid is
expected to be consumed total within 5 min. Blood sam-
ples will be taken after 2 h. Exclusion criteria for oral
glucose tolerance test are Diabetes Type I, use of insulin
and/or fasting blood glucose level exceeding 10 mmol/l.
Health related quality of life and fatigue
Quality of life will be self-reported and measured using
the generic, multi-purpose-form questionnaire for
Health related quality of life (HRQOL) called Short form
(SF) health survey consisting of 36 items (SF-36) [80].
The 36 items are categorized into eight multi-item
scales; 1) physical functioning, 2) role physical, 3) bodily
pain, 4) general health, 5) vitality, 6) social functioning,
7) role emotional and 8) mental health as well as a
single-item measuring health transition during the last
year. The data will first be standardized in order to com-
pare results across studies [80] and then recoded accord-
ing to a syntax developed by Loge et al [81].
A validated generic fatigue questionnaire (FQ) is used
to assess the patients subjective fatigue status (11 items)
and the duration and extent of fatigue (2 items) [82].
The FQ asks about fatigue symptoms experienced dur-
ing the last month compared to how the subject felt
when she/he was last feeling well [82–85]. Each item has
four response-choices [82]. The scoring of each response
is based on a Likert- (0, 1, 2, 3) and a dichotomized (0,
0, 1, 1) scale. The latter is only used for case definition.
The total sum of the Likert-scores is designated total fa-
tigue (TF) where higher scores imply more fatigue.
Assessment of new morbidity of diet-related chronic
diseases and adverse events
New morbidity of diet-related chronic diseases arising
after CRC diagnosis (e.g. ischemic coronary heart dis-
ease, cerebrovascular disease, thromboembolic disease,
diabetes, hypertension and chronic obstructive pulmon-
ary disease) will be collected from the national health
registries in Norway, a comorbidity questionnaire devel-
oped for this study designed to assess comorbidity based
on data from the third Norwegian population health
study (HUNT 3) [67], and from medical records. These
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data will be supplemented by data on drug use from the
Norwegian Prescription Register. Adverse events are re-
corded based on the Common Terminology Criteria for
Adverse Events (CTCAE, Version 4.0) [86].
Sample size
Calculation for primary outcomes
The sample size calculations are based on assuming a
Weibull distribution for the survival times in both arms.
We further assume a constant hazard ratio for the inter-
vention effect over time and that we have the same
follow-up of 5, 10, or 15 years, respectively, for all pa-
tients. Sample sizes required to achieve a statistical
power of 80% and significance level of 5% were calcu-
lated with computer simulations using the spower func-
tion in R (version 3.2.0) package Hmisc version 3.17–0.
Survival rates in the control group [2, 87] and expected
reduction in mortality rates in the intervention group
are taken from the literature (see Discussion, [88–93]).
With a 68% 5-year OS in the control group, we have
80% power to detect a 25% reduction in mortality due to
the intervention (corresponding to a hazard ratio of
0.71). The required total sample size is then 500 (250 in
each study group) (Table 6).
Moreover, sample size calculation based on 25% reduc-
tion in events of DFS after 5 years of surgery (59% 5-year
DFS in the control group), we have 80% power to detect
HR of 0.70, with 190 patients in each group (Table 6).
Stratified and subgroup analysis
All of the power calculations are based on a heteroge-
neous population of CRC patients.
Since post-surgery treatment may vary, and colon ver-
sus rectum cancer may respond differently to the diet
intervention, we will also perform stratified statistical
analysis. It is not known whether treatment effects are
different in these subgroups. These stratified analyses
will be conducted with primary outcomes at the later
time-points in the study and at all time-points to assess
mean differences between the control and the interven-
tion groups in biomarker analysis, as these data normally
require fewer patients per group.
Statistical analysis
Data will be analysed using SPSS (IBM SPSS Statistic
22). For the survival outcomes (primary outcome 1 and
2, and secondary outcomes I-VI) tests will be performed
to compare survival rates between the control and inter-
vention groups at 5, 10, and 15 years after baseline.
Survival probabilities will be estimated with the Kaplan-
Meier method. Cox proportional hazards models will be
used to identify prognostic and predictive biomarkers
for survival outcomes.
For non-survival secondary outcomes, parametric or
non-parametric tests for two-group comparisons will be
used to assess group differences at individual time-
points. In addition, mixed effect models for longitudinal
data and regression models will be used to evaluate associ-
ation and change over time in dietary intake, nutritional
status, body composition, molecular tumor characteristics,
physical function and activity, quality of life, fatigue and
treatment related outcomes and to examine differences
between the intervention and control groups. All statis-
tical tests are performed as two-sided tests. Effects are
considered statistically significant if p <0.05.
Discussion
The primary aims of the CRC-NORDIET are to study
whether a healthy diet rich in anti-inflammatory and
antioxidant-rich foods and based on the NFBDG can im-
prove DFS and OS in CRC patients. To our knowledge,
this is the first randomized controlled trial designed to
investigate the effect of a dietary intervention on these
outcomes in CRC patients, and to investigate the potential
role of diet in dampening of inflammation and oxidative
stress in these patients. The multiple strategies used to
achieve compliance to the intervention during the first
year, followed by the 14 years maintenance and follow-up
period make the design of this intervention unique.
Data on role of diet on disease outcomes and survival
in CRC survivors is limited. To date, several cohort
studies, but no RCTs have investigated the effects of
food-based dietary interventions on these outcomes.
Table 6 Sample size in each group (n) and hazard ratios (HRs*)
for selected scenarios of reduction in mortality by intervention.





















































* HR = hazard ratio of intervention versus control, which corresponds to the
assumed survival rate in the control group and assumed reduction in mortality
by intervention
DFS disease-free survival, OS overall survival
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Data from a US cohort study with stage III colon cancer
patients suggest that high intakes of red and processed
meat, fat, refined grains and dessert, i.e. a Western diet-
ary pattern, after diagnosis are associated with a signifi-
cantly reduced disease-free and OS [13]. Similar findings
are reported in a Canadian cohort study with CRC pa-
tients staged I-III, where patients with the highest intake
of processed meat the previous year before diagnosis
had an 82% increased risk of recurrence or death com-
pared with patients with the lowest intake [15].
Prospective cohort studies have consistently reported
that physical activity after colorectal cancer diagnosis re-
duces risk of mortality. In a meta-analysis of six pro-
spective cohort studies, including 7522 CRC survivors,
the authors observed that the most physical active survi-
vors had a 42% lower risk of total mortality compared to
those who were least active. The risk reduction of
cancer-specific mortality was 39% [94]. No RCT has so
far confirmed that physical activity impacts mortality in
CRC survivors.
Interventions designed to investigate the effect of diet
separated from other lifestyle factors (smoking, physical
activity, weight regulation) are needed in order to inves-
tigate whether there is a causal relationship between diet
and survival as well as disease-related outcomes. Our
intervention is intended to change the dietary habits to-
wards a diet in agreement with the NFBDG. These diet-
ary guidelines are developed to prevent chronic diseases,
including cancers, in the general population. Several
large cohort studies have shown that there is a consist-
ent inverse association between adherence to cancer pre-
vention guidelines and cancer-specific and all-cause
mortality [89, 95]. Among cancer survivors, reduction in
total mortality between highest versus lowest score in
adherence to diet recommendations has been docu-
mented in five different cohort studies, ranging from
24% to 36% (follow-up period from 3.7 to 13.6 years)
[88–93]. Association of adherence to American Cancer
Society guidelines and reduction in death attributed to
cancer has been shown to be 25 and 26% in men and
women, respectively [89]. Hastert et al documented an
association of adherence to the WCRF/AICR guidelines
and reduction in cancer-specific mortality of 61% in re-
spondents with the highest compared to the lowest
WCRF/AICR score (follow-up time of 7.7 years) [95].
Furthermore, NFBDG include advice regarding red
and processed meat, dietary fibre, dairy products and
garlic, all of which are related to risk of CRC. Whether
these dietary factors also may have effect on survival and
disease outcomes, remain unclear. With improvement in
cancer survival, these perspectives are increasingly im-
portant. The main objective of the present study is to
test if diet will improve survival and cancer-related out-
comes, mediated through reduced inflammation and
oxidative stress. To strengthen this assumption, we have
chosen to select specific foods within the NFBDG which
have been identified as anti-inflammatory or antioxidant-
rich in previous preclinical and clinical studies [23–29,
37–39, 41–48, 53, 55, 96].
Four aspects that may be of importance for achieving
lifestyle changes and facilitate compliance to the inter-
vention: 1) timing of intervention, 2) choice of motiv-
ational approach to achieve lifestyle changes, 3) duration
of intervention, and 4) use of incentives and methods to
achieve sustainable changes. Previous studies have
shown that cancer patients in general are particularly
motivated to change dietary habits at the time of diagno-
sis, often reported as the teachable moment [97–99]. In-
terventions designed to include this teachable moment
have shown to be successful [97–99]. In our trial, we
introduce the dietary intervention within a few months
from surgery, thereby expecting we reach the patients
within the time frame of this teachable moment. Fur-
thermore, principles from MI [61] are implemented in
each of the dietary counselling sessions by trained regis-
tered clinical dietitians. Previously published trials that
have succeeded in changing lifestyle behaviours in can-
cer patients are based on theoretical frameworks and
theories, including social cognitive behaviour therapy
and use of MI. It is emphasized that the patient defines
her/his own goals to increase the chances that he or she
will succeed in changing dietary habits. We suggest that
it is important to focus on a few realistic goals at the
time, instead of aiming at changing the whole diet im-
mediately. In addition, follow-up by the same registered
clinical dietitian during the entire intensive intervention
period may be of importance for the commitment to the
intervention goals.
In order to increase the chances of sustainable lifestyle
changes and compliance to the intervention, our inter-
vention consists of a one year intensive period and a
subsequent maintenance period which lasts for until
14 years. Taking into account that the teachable moment
may vary among the patients and it may take time to es-
tablish new sustainable dietary habits, the inclusion of a
maintenance period will probably be beneficial with re-
gard to an increased long-term adherence to the inter-
vention. Previous published trials that have failed in
compliance from the patients may have had too short
time frame of diet intervention.
Different strategies are reported to be effective in pro-
moting lifestyle changes in cancer survivors [14, 97, 98,
100, 101]. Interventions focusing on individual counsel-
ling [14, 98, 100], and also interventions with a mixed
strategy of individual in-person counselling, telephone
counselling and mailed materials [97, 101] have been
shown to be effective in health behaviour change among
CRC survivors. Thus, during the first year, the CRC-
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NORDIET study offers individualized counselling, free
foods, a discount card on healthy foods, access to a
login-restricted web page, printed materials, cooking
courses and inspiration day, which may all be effective
incentives to follow the NFBDG.
In placebo-controlled RCTs, an intervention is tested
by comparing one group of individuals who receive the
intervention with a control group who receives a pla-
cebo. This type of placebo-controlled RCT is most often
not possible when studying food-, or exercise-based in-
terventions, since placebo-foods or placebo-exercise do
not exist. In addition, no food based intervention can be
analysed thoroughly without considerations regarding
energy intake and energy expenditure. We have there-
fore selected to give the intervention group and the con-
trol group the same advice on physical activity. We
include careful monitoring of physical activity to control
for any confounding effects of physical activity. Of eth-
ical reasons, we also include standard dietary advice (i.e.
standard clinical care) in the control group, as well invi-
tations to group meetings and feed-back reports on
health status. Thus, while the control group in the
present study is not identical to a placebo group, this
particular study design was used in order to isolate the
effect of diet intervention on CRC patients, and to re-
duce drop-outs from the control group, which is a com-
mon concern in long-term intervention trials.
Sample size estimation is not straightforward in RCTs
with complex diet intervention and long term hard out-
comes. This is especially the case when no similar trials
have been previously published. By using the best avail-
able information from scientific literature and Norway
Cancer Registry on survival rates in the control group
and expected reduction in mortality rates in the inter-
vention group, we have performed power calculations on
the two primary outcomes after 5, 10 and 15 years after
baseline. We conclude that 250 patients in each group
would give us a reasonable chance (at 80% power) to de-
tect any significant effects (see Methods and Design sec-
tion for details) after 5, 10 and 15 years.
In a similar study, testing the effects of two different
6 months adjuvant cytostatic protocols (i.e. the MOSAIC
study [102]), 2246 patients who had undergone curative re-
section for stage II and III colon cancer, were recruited.
After a median follow-up for 38 months, fewer cancer-
related events was observed in the alternative treatment
group compared to the standard treatment group (HR 0.77,
p = 0.002). The main reason for the lower number of pa-
tients required in our CRC-NORDIET study compared to
the MOSAIC study is due to an older population with more
expected events (50–80 years versus 19–75 years) and a
longer follow-up time (10 and 15 years versus 3 years).
We have also performed a number of power esti-
mations on secondary outcomes (data not shown). In
general, the CRC-NORDIET study is expected to have
enough statistical power to detect significant effects in a
majority of these intermediate outcomes (to be pub-
lished in relevant reports). These power calculations on
primary and secondary outcomes are also supported
from the RCTs with physical activity intervention in
CRC and breast cancer patients; Friedenreich and Cour-
neya detected significant effects on intermediate out-
comes (e.g. inflammation biomarkers) as well as disease
outcomes in RCTs with 200–250 patients per group
[103–105].
Conclusion and perspectives
The CRC-NORDIET study investigates whether a diet
aimed at dampening inflammation and oxidative stress
and in full accordance with the NFBDG will improve
survival and disease outcomes in CRC patients. This
RCT is unique in several aspects related to the interven-
tions as well as outcomes. Since previous research on
the role of diet for CRC survivors is limited, the study is
important in order to improve health outcomes and sur-
vival in this population.
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